Leap Therapeutics announced that enrollment has been completed in Part A of the Phase 2 DeFianCe study evaluating DKN-01, Leap’s anti-Dickkopf-1 antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer. Initial data from the study is expected in mid-2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LPTX:
- Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- Leap Therapeutics reports Q4 EPS (11c), consensus (11c)
- Leap Therapeutics news ‘disappointing at first glance,’ says Piper Sandler
- Leap Therapeutics price target lowered to $2 from $3 at Mizuho
- Leap Therapeutics provides update on BeiGene option agreement for DKN-01
